期刊文献+

AMPK/SIRT1/NF-κB通路在糖尿病心肌病中的作用 被引量:5

Role of AMPK/SIRT1/NF-κB signaling pathway in diabetic cardiomyopathy
下载PDF
导出
摘要 糖尿病心肌病是糖尿病重要并发症之一,其发病机制涉及糖脂代谢紊乱、胰岛素抵抗、氧化应激、心肌细胞凋亡等诸多因素。腺苷酸活化蛋白激酶(AMPK)是机体能量的感受器,可以调节机体代谢状态并激活下游众多分子。SIRT1是一个去乙酰化酶,参与调节由能量限制引发的长寿作用。核转录因子-κB(NF-κB)参与多种炎症因子转录调控并发挥关键作用。研究表明这三者之间存在着相互调控关系,可形成AMPK/SIRT1/NF-κB通路对下游分子产生级联反应。该文主要关注该通路在糖尿病心肌病中的作用。 Diabetic cardiomyopathy is one of the vital complications of diabetes mellitus. The underlying pathogenesis is involved with glycolipid metabolic disorder,insulin resistance,oxidative stress,myocardial cell apoptosis and alternative multiple factors. As a cellular energy sensor,adenosine 5'-monophosphate-activated protein kinase( AMPK) can regulate the metabolic status and activate multiple molecules in the downstream signaling pathway. SIRT1 is nicotinamide adenine dinucleotide-dependent histone deacetylase,which participates in the regulation of longevity effect induced by calorie restriction. NF-κB plays a pivotal role in regulating the transcription of multiple inflammatory cytokines. These three cytokines exert a mutually regulatory effect,which lead to the cascade reaction of the molecules in the downstream AMPK/SIRT1/NF-κB signaling pathway.
出处 《新医学》 2017年第10期677-682,共6页 Journal of New Medicine
基金 广东省自然科学基金(2016A030313841)
关键词 糖尿病心肌病 腺苷酸活化蛋白激酶 SIRT1 核因子-KB 炎症反应 氧化应激 胰岛素抵抗 Diabetic cardiomyopathy Adenosine 5'-monophosphate-activated protein kinase SIRT1 Nuclear factor-κB Inflammatory response Oxidative stress Insulin resistance
  • 相关文献

参考文献1

二级参考文献17

  • 1尹翠梅,吕蕾,郭俊杰,刘亚丽,徐秀峰,刘照宏.化痰散结、活血化瘀治疗2型糖尿病血管病变[J].中国中医基础医学杂志,2006,12(3):202-204. 被引量:13
  • 2RESL M, HULSMANN M, PACHER R, et al. Heart failure in diabetes. Wien Med Wochenschr [ J ]. 2009, 159 (5-6): 134-140.
  • 3WILDING J P. The importance of free fatty acids in the development of type 2 diabete [ J ]. Diabet Med, 2007, 24 (9) : 934-945.
  • 4BUDHIRAJA S, SINGH J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications [J]. Fundam Clin Pharmacol, 2008, 22 (3): 231-240.
  • 5SUAREZ J, SCOTT B, DILLMANN W H. Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy [ J ]. Am J Physiol Regul Integr Comp Physiol, 2008, 295 (5) : R1439-R1445.
  • 6MARSTON S B, DE TOMBE P P. Troponin phosphorylation and myofilament Ca^2+ -sensitivity in heart failure: increased or decreased?[J]. Mol Cell Cardiol, 2008, 45 ( 5 ) : 603-607.
  • 7CAI L. Diabetic cardiomyopathy and its prevention by metallotbionein : experiment alevidenee, possible mechanisms and clinical implications [J]. Curr Med Chem, 2007, 14 (20): 2193-2203.
  • 8LEBECHE D, DAVIDOFF A J, HAJJAR R J. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy [ J ]. Nat Clin Pract Cardiovasc Med, 2008, 5 (11): 715-724.
  • 9KJAERGAARD J, HASTRUP SVENDSEN J, SOGAARD P, et al. Advanced quantitative echocard-iography in arrhythmogenic right ventricular cardiomyopathy [ J ]. J Am Soc Echocardiogr, 2007, 20 (1): 27-35.
  • 10CERGHIZAN A, BALA C, NITA C, et al. Practical aspects of the control of cardiovascular risk in type 2 diabetes and the metabolic syndrome [J]. Exp Clin Cardiol, 2007, 12 (2): 83-86.

共引文献7

同被引文献22

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部